Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 50 28 51 40 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046
UMLS 69 C0003537

Summaries for Aphasia

NINDS : 50 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Indiivfduals withanomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to frontotemporal lobar degeneration with tdp43 inclusions, grn-related and nominal aphasia, and has symptoms including central nervous system signs and symptoms, other speech disturbances and sleeplessness. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

MedlinePlus : 40 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 33.9 GRN MAPT
2 nominal aphasia 33.1 C9orf72 CHMP2B GRN MAPT PSEN1
3 progressive non-fluent aphasia 33.0 C9orf72 CHMP2B GRN MAPT PSEN1
4 semantic dementia 32.9 APOE GRN MAPT
5 agraphia 31.7 GRN MAPT PRNP PSEN1
6 apraxia 31.6 C9orf72 FOXP2 GRN MAPT
7 pick disease of brain 30.8 APOE APP GRN MAPT PSEN1 SNCA
8 alexia 30.7 APOE PSEN1
9 associative agnosia 30.4 GRN PSEN1
10 ideomotor apraxia 30.3 GRN MAPT PSEN1
11 creutzfeldt-jakob disease 30.2 APOE MAPT PRNP
12 mutism 30.1 CHMP2B GRN
13 posterior cortical atrophy 30.0 APOE MAPT
14 akinetic mutism 29.9 MAPT PRNP
15 echolalia 29.9 GRN MAPT PSEN1
16 visual agnosia 29.9 GRN PSEN1
17 prion disease 29.6 APP MAPT PRNP
18 kluver-bucy syndrome 29.6 APP MAPT PSEN1
19 speech disorder 29.5 FOXP2 GRIN2A GRN
20 frontotemporal dementia 29.5 APOE APP C9orf72 CHMP2B GRN LRRK2
21 motor neuron disease 29.4 C9orf72 GRN MAPT
22 supranuclear palsy, progressive, 1 29.3 APOE APP C9orf72 GRN LRRK2 MAPT
23 behavioral variant of frontotemporal dementia 28.9 C9orf72 CHMP2B GRN MAPT PSEN1
24 reading disorder 28.9 FOXP2 PSEN1
25 alzheimer disease 28.4 APOE APP GRIN2A GRN MAPT PRNP
26 dementia 28.2 APOE APP C9orf72 CHMP2B GRN MAPT
27 amyotrophic lateral sclerosis 1 27.6 APP C9orf72 CHMP2B GRN MAPT PRNP
28 epilepsy-aphasia spectrum 12.4
29 logopenic progressive aphasia 12.4
30 epilepsy, focal, with speech disorder and with or without mental retardation 12.0
31 landau-kleffner syndrome 11.9
32 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 11.8
33 intellectual disability-expressive aphasia-facial dysmorphism syndrome 11.8
34 masa syndrome 11.7
35 gerstmann syndrome 11.6
36 cerebral atrophy 11.4
37 moyamoya disease 1 11.1
38 marchiafava bignami disease 11.1
39 autosomal dominant partial epilepsy with auditory features 10.9
40 spastic paraplegia 1 10.8
41 sudanophilic cerebral sclerosis 10.8
42 frontotemporal dementia, chromosome 3-linked 10.8
43 progressive multifocal leukoencephalopathy 10.8
44 handl syndrome 10.8
45 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 10.8
46 myelinoclastic diffuse sclerosis 10.8
47 genetic prion diseases 10.4 APOE PRNP
48 senile plaque formation 10.4 APOE APP
49 phonagnosia 10.4 GRN PSEN1
50 writing disorder 10.3 GRN PSEN1

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


central nervous system signs and symptoms, other speech disturbances, sleeplessness, hot flushes, vertigo/dizziness, other symbolic dysfunction, other and unspecified speech disturbances, symptoms involving head and neck, scanning speech, sore throat, aphasic, aprosodia, swelling, mass, or lump in head and neck, chronic pain, vertigo, tremor, syncope, signs and symptoms, digestive, signs and symptoms, seizures, sciatica, pain, other symptoms involving head and neck, icterus, headache, fever, edema, dyspnea, cyanosis, cachexia, back pain

MGI Mouse Phenotypes related to Aphasia:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 PRNP PSEN1 SLC20A2 SNCA APOE APP
2 cellular MP:0005384 10.21 GRN L1CAM LRRK2 MAPT PRNP PSEN1
3 nervous system MP:0003631 10.18 APOE APP C9orf72 CHMP2B GRIN2A GRN
4 immune system MP:0005387 10.16 PSEN1 SLC20A2 SNCA APOE APP C9orf72
5 growth/size/body region MP:0005378 10.15 C9orf72 L1CAM MAPT PRNP PSEN1 SLC20A2
6 mortality/aging MP:0010768 10.14 APOE APP C9orf72 GRN L1CAM LRRK2
7 hematopoietic system MP:0005397 10.13 APOE APP C9orf72 GRN LRRK2 MAPT
8 integument MP:0010771 10.09 APOE APP GRIN2A L1CAM LRRK2 MAPT
9 no phenotypic analysis MP:0003012 9.97 APOE APP C9orf72 GRN L1CAM LRRK2
10 reproductive system MP:0005389 9.8 APOE APP GRN L1CAM PRNP PSEN1
11 skeleton MP:0005390 9.7 APOE L1CAM LRRK2 PRNP PSEN1 SLC20A2
12 vision/eye MP:0005391 9.17 MAPT PRNP PSEN1 SLC20A2 APOE GRN
13 taste/olfaction MP:0005394 9.13 APOE MAPT SNCA

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
4
Donepezil Approved Phase 4 120014-06-4 3152
5 Piracetam Approved, Investigational Phase 4,Phase 1 7491-74-9
6
Levodopa Approved Phase 4,Phase 2,Phase 3 59-92-7 6047
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Amantadine Approved Phase 4,Phase 2,Phase 3 768-94-5 2130
10 tannic acid Approved, Nutraceutical Phase 4,Phase 3
11
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
12 Antiparkinson Agents Phase 4,Phase 2,Phase 3
13 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
15 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
16 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
17 Cholinergic Agents Phase 4,Phase 2
18 Cholinesterase Inhibitors Phase 4,Phase 2
19 Nootropic Agents Phase 4,Phase 2,Phase 1
20 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
22 Autonomic Agents Phase 4,Phase 3,Phase 2
23 Dopamine agonists Phase 4
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
25 Antidepressive Agents Phase 4,Phase 2,Phase 1
26 Antidepressive Agents, Second-Generation Phase 4
27 Psychotropic Drugs Phase 4,Phase 2,Phase 1
28
Serotonin Phase 4 50-67-9 5202
29 Serotonin Agents Phase 4
30 Serotonin Uptake Inhibitors Phase 4
31 Analgesics Phase 4,Phase 2,Phase 3
32 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
33 Anti-Inflammatory Agents Phase 4,Phase 3
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Antipyretics Phase 4
36 Antirheumatic Agents Phase 4,Phase 2,Phase 3
37 Cyclooxygenase Inhibitors Phase 4
38 Fibrinolytic Agents Phase 4
39 Platelet Aggregation Inhibitors Phase 4
40 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1
41 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Pharmaceutical Solutions Phase 4
44
Carbidopa Approved Phase 2, Phase 3 28860-95-9 38101 34359
45
Methylene blue Approved, Investigational Phase 3 61-73-4
46
Miglustat Approved Phase 3,Phase 1 72599-27-0 51634
47
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
48
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
49
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
50
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 287)

# Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
7 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
8 Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke Completed NCT01762163 Phase 4 Qizhitongluo Capsule;Naoxintong Capsule;Aspirin Enteric-coated Tablets;placebo
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
11 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
12 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
13 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
14 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
15 Action of Amantadine on Post-Stroke Aphasic Patients Completed NCT00821691 Phase 2, Phase 3 Amantadin;Placebo
16 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
17 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
18 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
19 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
20 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3 HYCAMTIN, oral capsules
21 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
22 Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window Recruiting NCT00826059 Phase 3
23 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes Recruiting NCT02618577 Phase 3 Edoxaban;ASA
24 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
25 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
26 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
27 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Enrolling by invitation NCT02245568 Phase 3 TRx0237
28 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
29 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
30 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
31 Dextroamphetamine and tDCS to Improve the Fluency Unknown status NCT02514044 Phase 2 Dexedrine;Placebo
32 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
33 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
34 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
35 AERs in Aphasia: Severity and Improvement Completed NCT00013442 Phase 2
36 Psychosocial Wellbeing Following Stroke Completed NCT01912014 Phase 1, Phase 2
37 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease Completed NCT00814697 Phase 2
38 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
39 Posturing Effects on Perception of Time and Perceptions of the Provider-Patient Interaction in the Emergency Department Completed NCT00170105 Phase 2
40 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
41 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
42 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study Completed NCT00810095 Phase 2
43 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
44 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
45 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
46 tDCS and Aphasia Therapy in the Acute Phase After Stroke Recruiting NCT03297450 Phase 2
47 Evaluating Anodal tDCS Preceding Aphasia Therapy Recruiting NCT02249819 Phase 1, Phase 2
48 Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study Recruiting NCT02540109 Phase 2
49 Dosage and Predictors of Naming Treatment Response in Aphasia Recruiting NCT02005016 Phase 1, Phase 2
50 Effects of Transcranial Direct Current Stimulation in Post-stroke Aphasia Recruiting NCT02622945 Phase 2

Search NIH Clinical Center for Aphasia

Genetic Tests for Aphasia

Genetic tests related to Aphasia:

# Genetic test Affiliating Genes
1 Aphasia 28

Anatomical Context for Aphasia

MalaCards organs/tissues related to Aphasia:

38
Brain, Testes, Cortex, Bone, Temporal Lobe, Prefrontal Cortex, Eye

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 1067)
# Title Authors Year
1
Barriers and facilitators to meeting aphasia guideline recommendations: what factors influence speech pathologists' practice? ( 29376450 )
2018
2
Predicting Recovery in Acute Post-stroke Aphasia. ( 29451321 )
2018
3
Pre-articulatory electrical activity associated with correct naming in individuals with aphasia. ( 29421267 )
2018
4
Proform-Antecedent Linking in Individuals with Agrammatic Aphasia: A Test of the Intervener Hypothesis. ( 29422720 )
2018
5
Integration of speech and gesture in aphasia. ( 29411476 )
2018
6
GRIN2A mutations in epilepsy-aphasia spectrum disorders. ( 29056244 )
2018
7
Maximising recovery from aphasia with central and peripheral agraphia: The benefit of sequential treatments. ( 29298550 )
2018
8
A quick aphasia battery for efficient, reliable, and multidimensional assessment of language function. ( 29425241 )
2018
9
Sentence composition ability in two patients with non-fluent/agrammatic variant primary progressive aphasia. ( 29409157 )
2018
10
Primary progressive aphasia: a clinical approach. ( 29392464 )
2018
11
Long-Term maintenance of anomia treatment effects in primary progressive aphasia. ( 29380657 )
2018
12
A Computational Investigation of Sources of Variability in Sentence Comprehension Difficulty in Aphasia. ( 29356427 )
2018
13
Further Evidence of the Positive Influence of Repetitive Transcranial Magnetic Stimulation on Speech and Language in Patients with Aphasia after Stroke: Results from a Double-Blind Intervention with Sham Condition. ( 29402816 )
2018
14
Implementing a Standardized Assessment Battery for Aphasia in Acute Care. ( 29359304 )
2018
15
[18F]AV-1451 tau-PET and primary progressive aphasia. ( 29451323 )
2018
16
Atypical Kawasaki Disease Presenting with Hemiparesis and Aphasia: A Case Report. ( 29398757 )
2018
17
Words fail: Lesion-symptom mapping of errors of omission in post-stroke aphasia. ( 29411521 )
2018
18
Error Consistency in Acquired Apraxia of Speech With Aphasia: Effects of the Analysis Unit. ( 29392281 )
2018
19
Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. ( 29254097 )
2018
20
The language disorder of prion disease is characteristic of a dynamic aphasia and is rarely an isolated clinical feature. ( 29304167 )
2018
21
Anatomy of aphasia revisited. ( 29360947 )
2018
22
Cognitive functioning in chronic post-stroke aphasia. ( 29432034 )
2018
23
Repetitive sessions of tDCS to improve naming in post-stroke aphasia: Insights from an individual patient data (IPD) meta-analysis. ( 29439369 )
2018
24
The Nature of Error Consistency in Individuals With Acquired Apraxia of Speech and Aphasia. ( 28654943 )
2017
25
Reversible global aphasia as a side effect of quetiapine: a case report and literature review. ( 28894370 )
2017
26
Cholinergic depletion and basal forebrain volume in primary progressive aphasia. ( 28018854 )
2017
27
Functional activation independently contributes to naming ability and relates to lesion site in post-stroke aphasia. ( 28083891 )
2017
28
Semantic dementia, progressive non-fluent aphasia and their association with amyotrophic lateral sclerosis. ( 28554960 )
2017
29
Crossed Aphasia in a Patient with Anaplastic Astrocytoma of the Non-Dominant Hemisphere. ( 29299104 )
2017
30
[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. ( 28912300 )
2017
31
Limb apraxia and aphasia. ( 29236816 )
2017
32
Devising a Method to Study if Wernicke's Aphasia Patients are Aware That They Do Not Comprehend Language or Speak It Understandably. ( 29371852 )
2017
33
Cerebellar induced differential polyglot aphasia: A neurolinguistic and fMRI study. ( 28917165 )
2017
34
Globular glial tauopathy presenting as non-fluent/agrammatic variant primary progressive aphasia with chorea. ( 28923295 )
2017
35
Combined aphasia and apraxia of speech treatment (CAAST): Systematic replications in the development of a novel treatment. ( 28084854 )
2017
36
The development and feasibility of an online aphasia group intervention and networking program - TeleGAIN. ( 28868932 )
2017
37
Inner Speech's Relationship With Overt Speech in Poststroke Aphasia. ( 28885640 )
2017
38
Thinking on Treating Echolalia in Aphasia: Recommendations and Caveats for Future Research Directions. ( 28420974 )
2017
39
Ictal conduction aphasia and ictal angular gyrus syndrome as rare manifestations of epilepsy: The importance of ictal testing during video-EEG monitoring. ( 28913167 )
2017
40
Comparing phoneme frequency, age of acquisition, and loss in aphasia: Implications for phonological universals. ( 28914137 )
2017
41
The Epilepsy-Aphasia Spectrum: From Landau-Kleffner Syndrome to Rolandic Epilepsy. ( 28628937 )
2017
42
Short Version of the Bilingual Aphasia Test in Malayalam. ( 28904451 )
2017
43
Effects of semantic weight on verb retrieval in individuals with aphasia: A different perspective. ( 28898710 )
2017
44
Emotion detection deficits and changes in personality traits linked to loss of white matter integrity in primary progressive aphasia. ( 28879086 )
2017
45
Frequency of CNKSR2 mutation in the X-linked epilepsy-aphasia spectrum. ( 28098945 )
2017
46
Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. ( 28515265 )
2017
47
Naming unique entities in the semantic variant of primary progressive aphasia and Alzheimer's disease: Towards a better understanding of the semantic impairment. ( 27939367 )
2017
48
Effectiveness of speech language therapy either alone or with add-on computer-based language therapy software (Malayalam version) for early post stroke aphasia: A feasibility study. ( 28870554 )
2017
49
Aphasia As a Predictor of Stroke Outcome. ( 28929424 )
2017
50
Fidelity to a motivational interviewing intervention for those with post-stroke aphasia: a small-scale feasibility study. ( 28950785 )
2017

Variations for Aphasia

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

Pathways for Aphasia

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 endosome GO:0005768 9.93 APP C9orf72 CHMP2B GRN LRRK2
2 cell surface GO:0009986 9.92 APP GRIN2A L1CAM PRNP PSEN1
3 neuron projection GO:0043005 9.87 APP GRIN2A LRRK2 PSEN1
4 membrane raft GO:0045121 9.81 APP LRRK2 PRNP PSEN1
5 lysosome GO:0005764 9.77 C9orf72 CHMP2B GRN LRRK2 SNCA
6 synaptic vesicle GO:0008021 9.75 GRIN2A LRRK2 SNCA
7 neuronal cell body GO:0043025 9.73 APOE L1CAM LRRK2 MAPT PSEN1 SNCA
8 terminal bouton GO:0043195 9.67 APP LRRK2 SNCA
9 rough endoplasmic reticulum GO:0005791 9.63 APP PSEN1 SNCA
10 axon GO:0030424 9.63 APP L1CAM LRRK2 MAPT PSEN1 SNCA
11 smooth endoplasmic reticulum GO:0005790 9.61 APP PSEN1
12 nuclear outer membrane GO:0005640 9.61 PSEN1 SNCA
13 postsynapse GO:0098794 9.61 LRRK2 PRNP SNCA
14 axonal growth cone GO:0044295 9.6 C9orf72 L1CAM
15 amyloid-beta complex GO:0106003 9.56 APOE PRNP
16 ciliary rootlet GO:0035253 9.55 APP PSEN1
17 inclusion body GO:0016234 9.5 LRRK2 PRNP SNCA
18 dendrite GO:0030425 9.5 APOE C9orf72 L1CAM LRRK2 MAPT PRNP
19 main axon GO:0044304 9.4 APP C9orf72
20 growth cone GO:0030426 9.1 APP L1CAM LRRK2 MAPT PSEN1 SNCA
21 plasma membrane GO:0005886 10.22 APOE APP CHMP2B GRIN2A L1CAM LRRK2
22 endoplasmic reticulum GO:0005783 10.07 APOE GRIN2A GRN LRRK2 PRNP PSEN1
23 Golgi apparatus GO:0005794 10.06 APOE APP LRRK2 PRNP PSEN1 SNCA

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.89 APP LRRK2 PSEN1
2 cellular protein metabolic process GO:0044267 9.88 APOE APP PSEN1 SNCA
3 negative regulation of neuron apoptotic process GO:0043524 9.87 APOE PSEN1 SNCA
4 neuron projection development GO:0031175 9.86 APP L1CAM MAPT
5 autophagy GO:0006914 9.85 C9orf72 CHMP2B LRRK2 PSEN1
6 excitatory postsynaptic potential GO:0060079 9.81 GRIN2A LRRK2 SNCA
7 response to oxidative stress GO:0006979 9.8 APOE APP LRRK2 PRNP PSEN1
8 forebrain development GO:0030900 9.79 APP FOXP2 PSEN1
9 memory GO:0007613 9.78 GRIN2A MAPT PSEN1
10 learning or memory GO:0007611 9.78 APP GRIN2A PRNP PSEN1
11 positive regulation of protein binding GO:0032092 9.77 APP LRRK2 PSEN1
12 regulation of autophagy GO:0010506 9.75 C9orf72 LRRK2 MAPT
13 negative regulation of neuron death GO:1901215 9.74 APOE LRRK2 SNCA
14 regulation of canonical Wnt signaling pathway GO:0060828 9.71 LRRK2 PSEN1
15 regulation of synaptic transmission, glutamatergic GO:0051966 9.71 LRRK2 PSEN1
16 positive regulation of dendritic spine development GO:0060999 9.71 APOE PSEN1
17 ionotropic glutamate receptor signaling pathway GO:0035235 9.71 APP GRIN2A
18 positive regulation of endocytosis GO:0045807 9.7 APOE SNCA
19 regulation of protein binding GO:0043393 9.7 APP PSEN1
20 regulation of neuronal synaptic plasticity GO:0048168 9.7 APOE SNCA
21 regulation of neuron death GO:1901214 9.69 LRRK2 SNCA
22 regulation of long-term neuronal synaptic plasticity GO:0048169 9.69 APP SNCA
23 positive regulation of neuron death GO:1901216 9.69 MAPT PRNP SNCA
24 positive regulation of long-term synaptic potentiation GO:1900273 9.68 APP GRIN2A
25 microglial cell activation GO:0001774 9.68 MAPT SNCA
26 dopamine metabolic process GO:0042417 9.68 GRIN2A SNCA
27 positive regulation of receptor recycling GO:0001921 9.68 PSEN1 SNCA
28 locomotory exploration behavior GO:0035641 9.67 APOE LRRK2
29 supramolecular fiber organization GO:0097435 9.67 MAPT SNCA
30 cellular response to copper ion GO:0071280 9.67 PRNP SNCA
31 cellular copper ion homeostasis GO:0006878 9.66 APP PRNP
32 negative regulation of protein processing GO:0010955 9.66 LRRK2 PRNP
33 positive regulation of protein import into nucleus, translocation GO:0033160 9.65 LRRK2 PSEN1
34 amyloid precursor protein metabolic process GO:0042982 9.65 APOE PSEN1
35 locomotion GO:0040011 9.65 GRIN2A PSEN1
36 amyloid fibril formation GO:1990000 9.64 APP MAPT
37 negative regulation of amyloid-beta formation GO:1902430 9.63 APOE PRNP
38 regulation of locomotion GO:0040012 9.63 LRRK2 SNCA
39 astrocyte activation GO:0048143 9.63 APP MAPT PSEN1
40 regulation of mitochondrial fission GO:0090140 9.62 LRRK2 MAPT
41 intracellular distribution of mitochondria GO:0048312 9.62 LRRK2 MAPT
42 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APOE APP PRNP
43 positive regulation of microglial cell activation GO:1903980 9.6 APP LRRK2
44 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.56 APP PSEN1
45 astrocyte activation involved in immune response GO:0002265 9.54 APP PSEN1
46 modulation of age-related behavioral decline GO:0090647 9.54 APP PRNP PSEN1
47 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.52 APP PSEN1
48 neuron projection maintenance GO:1990535 9.5 APP PRNP PSEN1
49 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.49 APP PSEN1
50 cellular response to amyloid-beta GO:1904646 9.46 APP GRIN2A PRNP PSEN1

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.62 LRRK2 MAPT PRNP SNCA
2 tau protein binding GO:0048156 9.37 APOE SNCA
3 cuprous ion binding GO:1903136 9.26 PRNP SNCA
4 identical protein binding GO:0042802 9.17 APOE APP FOXP2 LRRK2 MAPT PRNP
5 lipoprotein particle binding GO:0071813 9.16 APOE MAPT
6 tubulin binding GO:0015631 9.13 LRRK2 MAPT PRNP
7 protein binding GO:0005515 10.22 APOE APP C9orf72 CHMP2B FOXP2 GRIN2A

Sources for Aphasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....